Uniwersytet Medyczny W Lublinie

4 trials 1 recruiting Academic / non-commercial

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

1 Recruiting

1 Completed trials

1 Countries active

11 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I/II

Phase IV

Phase III: 1 Phase II: 1 Phase I/II: 1 Phase IV: 1

100%

1 of 1 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Fallopian tube cancer 1 Ovarian cancer 1 Myasthenia gravis 1 Lichen sclerosus 1

Top IMPs

DARATUMUMAB 1 OBINUTUZUMAB 1 VENETOCLAX 1

All trials

4 total

The assessment of bevacizumab dose equivalence in ovarian cancer Pending

2023-509659-15-00 Phase IV 1 country
A study aimed at Optimise and Personalise Immunological Therapy of relapsed chronic lymphocytic leukaemia patients (OPTIC) Pending

2024-513917-11-01 Phase I/II 1 country DARATUMUMAB; OBINUTUZUMAB; VENETOCLAX
Clobetasol, mometasone and tacrolimus therapy in the treatment of vulval lichen sclerosus in the pediatric population. Recruiting

2024-514003-33-00 Phase III 1 country
Cladribine therapy in Myasthenia Ended

2024-517083-32-00 Phase II 1 country

Showing 1–4 of 4 trials

← All sponsors A–Z